The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.

Click Search to look for specific questions in SINQ or to select questions for a Report.

If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.

Recent Questions
<< First    < Prev 10    11 to 20 of 2100    Next 10 >    Last >>
Add to Report ID Question Status Last Updated
20190016

SS2018/Lymph nodes--Breast:  Should Code 3 of the Summary Stage 2018 (SS2018) for Breast designate the intramammary and infraclavicular lymph nodes as being ipsilateral? Similarly, should Code 7 designate infraclavicular lymph nodes as contralateral/bilateral? Laterality (ipsilateral, contralateral/bilateral) is included for axillary and internal mammary nodes in the respective codes.

Final Feb 27 2019
20190015

EOD 2018--EOD Primary Tumor: Should Note 6 in Extent of Disease (EOD) Primary Tumor for the schemas Fallopian Tube, Ovary, and Primary Peritoneal Carcinoma be revised to exclude pelvic sites? See Discussion.

Final Feb 21 2019
20190014

Reportability--Behavior: Is severe dysplasia reportable if it shows invasion or microinvasion pathologically? See Discussion.
 

Final Feb 13 2019
20190013

Laterality--Head and Neck:  Were the topography codes C090 and C091 intentionally left off of the Sites for Which Laterality Codes Must Be Recorded table in the 2018 SEER Manual?  The codes were also removed from Table 10 in the 2018 Solid Tumor Rules for Head and Neck but appear under coding instructions 1b. and 6b. in the manual.

Final Feb 13 2019
20190011

Reportability--Skin:  Is an atypical smooth muscle cell proliferation of the skin reportable? See Discussion.
 

Final Feb 01 2019
20190010

Reportability/Histology--Bladder:  Is papillary urothelial neoplasm of low malignant potential (PUNLMP) (8130/1) reportable when also referred to as papillary transitional cell carcinoma, grade 1, no invasion (8130/2) previously?  See Discussion.

Final Jan 28 2019
20190009

First Course Treatment/Surgery of Primary Site--Breast:  How is "Goldilocks," also referred to as oncoplastic reconstruction, in the surgery section for breast cancer patients coded?

Final Jan 24 2019
20190007

Reportability--Skin: Is atypical intradermal smooth muscle neoplasm (AISMN) of the skin reportable? The comment on the path report states: Atypical intradermal smooth muscle neoplasm (AISMN) was previously termed "cutaneous leiomyosarcoma."

Final Jan 14 2019
20190006

MP/H Rules/Multiple primaries--Breast:  Please confirm Multiple Primaries/Histology Breast Rule M8 applies in this 2017 case. The surgical resection is >60 days past the biopsy date but is it possible treatment plans for breast could span >60 days and this is one primary?  See Discussion.

Final Jan 08 2019
20190004

Systemic/Surgery Sequence: Does the Systemic/Surgery Sequence field apply to only the first surgery performed (Date of First Surgical Procedure) or does it apply to the most definitive surgery (Date Most Definitive Surgery) as well? See Discussion.

 

Final Jan 02 2019
< Prev 10    Next 10 >